|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Phase Ⅰ and pharmacokinetic study of etaracizumab (Abegrin) , a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors显示文摘 | Delbaldo C Raymond E Vera K | 2008 | Invest New Drugs2008，26，1： | 1 |
| 2 | Safety,pharmacokinetic,and antitumor activity of SU11248,a novel oral multitarget tyrosine kinase inhibitor,in patients with cancer显示文摘 | Faivre S Delbaldo C Vera K | 2006 | J Clin Oncol2006，24，1： | 1 |
| 3 | Safety, pharmacokinetic, and antitumor activity of SUl1248, a novel oral multitarget tyrosine kinase inhibitor,in patients with cancer显示文摘 | FAIVRE S DELBALDO C VERA K | 2006 | J ClinOnco12006，24，1： | 1 |
| 4 | Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors, Invest 显示文摘 | Delbaldo C Raymond E Vera K | 2008 | New Drugs2008，26，： | 1 |
| 5 | Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral muhitarget tyrosine kinase inhibitor, in patients with cancer 显示文摘 | Faivre S Delbaldo C Vera K | 2006 | J Clin Oncol2006，24，： | 1 |
| 6 | Phyllodes tumors and breast sarcomas:a review显示文摘 | Grenier J Delbaldo C Zelek L | | 0，，10： | 1 |
| 7 | Adding a second or a third drug to a chemotherapy regimen in patients with ad?vanced non-small-cell lung carcinoma (NSCLC): A meta?analysis of the literature显示文摘 | Delbaldo C Syz N Michiels S et aI | 2003 | Proc Am Soc Clin Oncol2003，22，20： | 1 |
| 8 | Safety,pharmacokinetic,and antitumor activity of SU11248,a novel oral multitarget tyrosine kinase inhibitor,in patients with cancer显示文摘 | FAIVRE S DELBALDO C VERA K | 2006 | J Clin Oncol2006，24，1： | 1 |
| 9 | Safety, pharmaco-kinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer显示文摘 | FAIVRE S DELBALDO C VERA K | 2006 | J Clin Oncol2006，24，1： | 1 |
| 10 | Second or third additional chemotherapy drag for non-small cell lung cancer in patients with advanced disease 显示文摘 | Delbaldo C Michiels S Rolland E | 2007 | Cochrane Database Syst Rev2007，，： | 1 |
| 11 | Phase I and pharma-cokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies 显示文摘 | Faivre S Chièze S Delbaldo C | 2005 | J Clin Oncol2005，23，： | 1 |
| 12 | Stents for palliation of obstructive metastatic colon cancer: impact on management and chemotherapy administration 显示文摘 | Karoui M Charachon A Delbaldo C | 2007 | Arch Surg2007，142，7： | 1 |
| 13 | 5-Fluorouracil / leucovorin combined with irinotecan and oxalipla-tin (FOLFIRINOX)as second-line chemotherapy in patients withmetastatic pancreatic adenocarcinoma显示文摘 | ASSAF E VERLINDE-CARVALHO M DELBALDO C | 2011 | Oncology2011，80，56： | 1 |
| 14 | Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors 显示文摘 | Delbaldo C Raymond E Vera K | 2008 | lnvest New Drugs2008，26，1： | 1 |
| 15 | Safety, pharmacokinetic, andantitumor activity of SUl1248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer 显示文摘 | Faivre S Delbaldo C Vera K | 2006 | J Clin Oncol2006，24，1： | 1 |
| 16 | Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer 显示文摘 | Faivre S Delbaldo C Vera K | 2006 | J Clin Oncol2006，24，1： | 1 |
| 17 | Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in pa- tients with cancer 显示文摘 | FAIVRE S DELBALDO C VERA K | 2006 | J Clin Oncol2006，24，1： | 1 |
| 18 | Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer显示文摘 | Catherine Delbaldo Stefan Michiels Nathalie Syz | 2004 | JAMA2004，292，： | 1 |
| 19 | Safety, pharmacoki- netic, and antitumor activity of SUl1248, a novel oral muhitarget tyrosine kinase inhibitor, in patients with cancer 显示文摘 | FAIVRE S DELBALDO C VERA K | 2006 | J Clin Oncol2006，24，1： | 1 |
| 20 | Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer显示文摘 | Faivre S Delbaldo C Vera K | 2006 | J Clin Oncol2006，24，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员